Company / Named in our posts
Cara Therapeutics, Inc..
Follow Cara Therapeutics, Inc.A clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases.[1]
03Deals
Deals on Carrywatch
Every deal that names Cara Therapeutics, Inc., and its role in each.
Cara Therapeutics, Inc. / Tvardi Operating Company, Inc. (f/k/a Tvardi Therapeutics, Inc.)
Cara Therapeutics and Tvardi Operating Company complete merger transaction
See deal detailsCara Therapeutics, Inc. / Tvardi Therapeutics, Inc.
Cara Therapeutics and Tvardi Therapeutics complete merger
See deal detailsHCR / Cara Therapeutics, Inc.
Cara Therapeutics sells royalty interests to HCR
See deal detailsDeal Web
Cara Therapeutics, Inc. and 1 firm it shares a posted deal with, and the path to any other firm.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Tvardi Management’s Discussion and Analysis of Financial Condition and Results of Operations
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02Tvardi Therapeutics, Inc. Form 8-K/A
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Cara Therapeutics, Inc.:
- P01
- P02
- P03